Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

A Lucid Group social

The newly formed Lucid Social Committee is launching its first event for the year: Today, on Thursday 24 February Lucid will be hosting its inaugural board games night in both...

Lucid Group Communications Limited

Rare Disease Day logo

Welcome to the era of the orphan drug

As we approach Rare Disease Day on 28 February, we look back at how the rare disease landscape has evolved over the last few decades.

Sciterion

- PMLiVE

London High Court rules in favour of NHS in Servier drug dispute

The judgement is a key milestone in the 11-year case between the French pharmaceutical company and the secretary of state for health and social care and the wider NHS

- PMLiVE

Eli Lilly launches the Institute for Genetic Medicine and a $700m facility investment

The US state-of-the-art facility will further the development of RNA and DNA-based treatments

Strictly personal: how to deliver 360-degree engagement to support your organisation’s agility and impact

By Simon Grime

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Inizio

- PMLiVE

England to end COVID-19 isolation laws and mass free testing

From 24 February, all COVID-19 restrictions will end in England and from 1 April, all free mass testing will finish

- PMLiVE

COVID-19 booster to be made available to those over 75 and high risk adults and children

Around 7.2 million people living in the UK aged over 75 – having already had their primary course of COVID-19 vaccines – will be eligible for the booster

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

Biomarin

FDA keeps BioMarin’s gene therapy for phenylketonuria on hold

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

EU flag

Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe

The once-daily oral drug is the first medicine approved in Europe to treat the condition in adults and paediatric patients 12 years and older

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links